

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAREPTA THERAPEUTICS, INC.,
Petitioners,

v.

GENZYME CORPORATION,
Patent Owner.

Case No. IPR2026-00270
Patent No. 12,298,313

PATENT OWNER'S UPDATED MANDATORY NOTICES

UPDATED MANDATORY NOTICES UNDER 37 C.F.R. § 42.8

Pursuant to 37 C.F.R. § 42.8, Patent Owner Genzyme Corporation updates its Mandatory Notices to reflect the status of related patents challenged by Petitioner in co-pending petitions as denied institution of *inter partes* review:

I. Related Matters Under 37 C.F.R. § 42.8(b)(2)

A. U.S. District Court for District of Delaware Related Matters

The following pending district court litigation may affect or be affected by this proceeding: *Genzyme Corp v. Sarepta Therapeutics, Inc.*, C.A. No. 24-cv-00882-RGA (D. Del.).

B. Patent Trial and Appeal Board Co-Pending Matters

Petitioner filed an *Inter Partes* Review (“IPR”) Petition challenging the patentability of certain claims of U.S. Patent No. 12,298,313 (the “’313 patent”) in IPR2026-00166, U.S. Patent No. 11,698,377 (the “’377 patent”) in IPR2026-00167, and U.S. Patent No. 12,123,880 (the “’880 patent”) in IPR2026-00168.

The ’313 patent is the same patent challenged in this IPR, and the ’377 and ’880 patents are related to the ’313 patent. Those IPRs may affect indirectly or may be affected by the decision in this proceeding since the patents are related and involved in the Delaware litigation (*supra* § II.A). Petitioner filed an authorized and unopposed motion to withdraw IPR2026-00166 on February 26, 2026, which

was granted on March 25, 2026. *See Sarepta Therapeutics, Inc. v. Genzyme Corp*, IPR2026-00166, Paper 12 (PTAB March 25, 2026)

On May 15, 2026, institution of *Inter Partes* Review was denied in IPR2026-00167 and IPR2026-00168. *See Sarepta Therapeutics, Inc. v. Genzyme Corp*, IPR2026-00167, -00168 Paper 13 (Director May 15, 2026) (“Pursuant to 35 U.S.C. § 314(a), after review of the merits, the petitioner has failed to show a reasonable likelihood of prevailing with respect to at least one of the claims challenged in the petition”).

Date: June 8, 2026

/Blaine M. Hackman/

Blaine M. Hackman, Reg. No. 67,479

Dechert LLP

Three Bryant Park

1095 Avenue of the Americas

New York, NY 10036-6797

Tel: 212-698-3500

Fax: 212-698-3599

blaine.hackman@dechert.com

Counsel for Patent Owner,

Genzyme Corporation

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that today in:

Sarepta Therapeutics, Inc., v. Genzyme Corporation, IPR2026-00270

I caused to be served a copy of:

PATENT OWNER'S UPDATED MANDATORY NOTICES

upon:

Sarepta Therapeutics, Inc. c/o:

robertwilson@quinnemanuel.com
annetoker@quinnemanuel.com
jimglass@quinnemanuel.com

via:

electronic service to the email addresses above.

Date: June 8, 2026

/Blaine M. Hackman/
Blaine M. Hackman, Reg. No. 67,479
Dechert LLP
Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
Tel: 212-698-3500
Fax: 212-698-3599
blaine.hackman@dechert.com
Counsel for Patent Owner,
Genzyme Corporation